Novo Nordisk applies for FDA approval of faster-acting diabetes drug
Wednesday, December 09, 2015
Danish insulin maker Novo Nordisk said it has applied to the U.S. Food and Drug Administration for approval of its faster-acting insulin drug aspart.
The filing came after results of a clinical trial programme involving around 2,100 people with diabetes.
reuters.com
